Research & Education

IASLC Chicago Multidisciplinary Symposium and ESMO 2016 Annual Meeting: 2016 Review

November 16, 2016 at 9:00PM EST - Recording Available



Thomas Stinchcombe, MD
Instructor, Temporary
Department of Medicine
Duke University School of Medicine

Ramaswamy Govindan, MD - Program Chair
Co-Director, Section of Medical Oncology
Professor of Medicine
Anheuser-Busch Endowed Chair in Medical Oncology
Director, Section of Oncology
Washington University School of Medicine

Name of Reviewer(s): 


Laurie Gaspar, MD –Nothing to Disclose

Name of Planner(s): 


Pia Hirsch-Nothing to Disclose      Carlos Ferreira-Nothing to Disclose

Name of Activity: 


IASLC Chicago Multidisciplinary Symposium and ESMO 2016 Annual Meeting: 2016 Review

Date of Activity:



COI Resolution: Ensure a balanced discussion of alternative. Do not use trade names. Do not refer to company names or logos. Do not recommend therapies.

“All planning committee members’ and/or faculty’s identified conflicts of interest pertaining to this activity were resolved prior to the activity.”

Speaker: Thomas Stinchcombe, MD-

Speaker/Advisory Board: Ariad, Helsinn, BI and Celgene.

Program Chair: Ramaswamy Govindan, MD-

Speakers or Advisory Board , Honoraria and consulting with the following: BI, GSK, Celgene, Roche, Bayer, Genentech, Clovis, Helsinn Healthcare, ARAID Pharmaceuticals, Astellas; Honoraruim with the following: Baxalta, Roche

Type of Activity:

 Live Course

  Internet Live Course (Webinar)XXXX

 Internet Enduring Material

Are there Commercial Supporters for this activity?


If yes, please list:

Recent meetings of the European Society of Medical Oncology (October 7-11, 2016) and the IASLC Chicago Multidisciplinary Symposium in Thoracic Oncology (September 22-24, 2016) provided important updates and new information relevant to the multidisciplinary management of patients with lung cancer.

In this webinar, Dr. Thomas Stinchcombe will identify and discuss the key abstracts, presentations and developments reported at these meetings, and:

  • provide an update on scientific progress in the diagnosis, treatment and management of thoracic malignancies;
  • focus on those developments most readily impacting  standards of care;
  • identify ongoing clinical trials that are likely to impact patient care in the near future.

After attending this program, participants will:

  • appraise clinical developments and  the impact on individual patient care;
  • employ new approaches to optimize treatment and management options in the personalized medicine paradigm;
  • consider opportunities for clinical trial participation.

Following the presentation, there will be ample time for discussion and a question/answer session. Attendees will be able to submit questions and comments to Dr. Stinchcombe via internet chat.


Financial/Commercial and Conflists of Interest Disclosures

IASLC Financial/Commercial Relationships and Conflicts of Interest Policy

IASLC Honoraria Policy

IASLC Commercial Support Agreement (LOA)

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants. 

In order to receive CME credit, attendees must fill out a program evaluation.


Please complete the evaluation link provided to you after the activity. The Certificate of credit will be ready for you to print or save for your records.

IASLC Lung Cancer Grand Rounds webinars will continue throughout 2016. The goal is to hold one program monthly. Participants who complete a pre-and post-test along with an evaluation will receive 1 AMA PRA Category 1 CreditTM for each completed webinar.

Use the Time Zone Converter